|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HBP1 |
Gene summary for HBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HBP1 | Gene ID | 26959 |
| Gene name | HMG-box transcription factor 1 | |
| Gene Alias | HBP1 | |
| Cytomap | 7q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DJ36 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26959 | HBP1 | LZE4T | Human | Esophagus | ESCC | 1.07e-07 | 4.37e-01 | 0.0811 |
| 26959 | HBP1 | LZE7T | Human | Esophagus | ESCC | 1.43e-04 | 2.99e-01 | 0.0667 |
| 26959 | HBP1 | LZE8T | Human | Esophagus | ESCC | 2.49e-15 | 2.16e-01 | 0.067 |
| 26959 | HBP1 | LZE20T | Human | Esophagus | ESCC | 1.22e-03 | 3.93e-01 | 0.0662 |
| 26959 | HBP1 | LZE22D1 | Human | Esophagus | HGIN | 1.02e-02 | -4.29e-02 | 0.0595 |
| 26959 | HBP1 | LZE22T | Human | Esophagus | ESCC | 3.31e-02 | 1.31e-01 | 0.068 |
| 26959 | HBP1 | LZE24T | Human | Esophagus | ESCC | 6.50e-12 | 6.34e-01 | 0.0596 |
| 26959 | HBP1 | LZE21T | Human | Esophagus | ESCC | 1.49e-06 | 1.55e-01 | 0.0655 |
| 26959 | HBP1 | LZE6T | Human | Esophagus | ESCC | 5.27e-05 | 2.69e-01 | 0.0845 |
| 26959 | HBP1 | P2T-E | Human | Esophagus | ESCC | 1.68e-24 | 3.32e-01 | 0.1177 |
| 26959 | HBP1 | P4T-E | Human | Esophagus | ESCC | 6.24e-19 | 3.94e-01 | 0.1323 |
| 26959 | HBP1 | P5T-E | Human | Esophagus | ESCC | 4.37e-14 | -5.23e-02 | 0.1327 |
| 26959 | HBP1 | P8T-E | Human | Esophagus | ESCC | 3.31e-23 | 5.62e-01 | 0.0889 |
| 26959 | HBP1 | P9T-E | Human | Esophagus | ESCC | 5.31e-16 | 4.78e-01 | 0.1131 |
| 26959 | HBP1 | P10T-E | Human | Esophagus | ESCC | 1.57e-23 | 5.08e-01 | 0.116 |
| 26959 | HBP1 | P11T-E | Human | Esophagus | ESCC | 1.01e-19 | 9.10e-01 | 0.1426 |
| 26959 | HBP1 | P12T-E | Human | Esophagus | ESCC | 1.12e-28 | 9.07e-01 | 0.1122 |
| 26959 | HBP1 | P15T-E | Human | Esophagus | ESCC | 9.64e-39 | 1.06e+00 | 0.1149 |
| 26959 | HBP1 | P16T-E | Human | Esophagus | ESCC | 5.29e-27 | 7.55e-01 | 0.1153 |
| 26959 | HBP1 | P17T-E | Human | Esophagus | ESCC | 9.98e-05 | 5.50e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605516 | Esophagus | HGIN | Wnt signaling pathway | 83/2587 | 444/18723 | 2.27e-03 | 2.33e-02 | 83 |
| GO:019873816 | Esophagus | HGIN | cell-cell signaling by wnt | 83/2587 | 446/18723 | 2.58e-03 | 2.55e-02 | 83 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:001605511 | Liver | Cirrhotic | Wnt signaling pathway | 150/4634 | 444/18723 | 9.75e-06 | 1.42e-04 | 150 |
| GO:019873811 | Liver | Cirrhotic | cell-cell signaling by wnt | 150/4634 | 446/18723 | 1.28e-05 | 1.80e-04 | 150 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
| GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
| GO:001605532 | Oral cavity | NEOLP | Wnt signaling pathway | 93/2005 | 444/18723 | 1.35e-10 | 1.34e-08 | 93 |
| GO:019873832 | Oral cavity | NEOLP | cell-cell signaling by wnt | 93/2005 | 446/18723 | 1.73e-10 | 1.66e-08 | 93 |
| GO:00160559 | Prostate | BPH | Wnt signaling pathway | 126/3107 | 444/18723 | 2.27e-10 | 1.23e-08 | 126 |
| GO:01987389 | Prostate | BPH | cell-cell signaling by wnt | 126/3107 | 446/18723 | 3.11e-10 | 1.67e-08 | 126 |
| GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
| GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
| GO:001605520 | Thyroid | HT | Wnt signaling pathway | 48/1272 | 444/18723 | 9.68e-04 | 9.93e-03 | 48 |
| GO:019873820 | Thyroid | HT | cell-cell signaling by wnt | 48/1272 | 446/18723 | 1.07e-03 | 1.07e-02 | 48 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| HBP1 | CD4TN | Breast | ADJ | SAMSN1,SARAF,GCLC, etc. | 2.76e-02 |  |
| HBP1 | NK | Breast | ADJ | SAMSN1,SARAF,GCLC, etc. | 3.22e-02 | |
| HBP1 | DC | Breast | DCIS | SAMSN1,SARAF,GCLC, etc. | 6.81e-02 |  |
| HBP1 | CD8TRM | Breast | DCIS | SAMSN1,SARAF,GCLC, etc. | 1.38e-02 | |
| HBP1 | MAST | Breast | Healthy | SAMSN1,SARAF,GCLC, etc. | 3.10e-02 |  |
| HBP1 | GC | Breast | Healthy | SAMSN1,SARAF,GCLC, etc. | 0.00e+00 | |
| HBP1 | M2MAC | Breast | Healthy | SAMSN1,SARAF,GCLC, etc. | 7.47e-04 | |
| HBP1 | MAST | Breast | IDC | SAMSN1,SARAF,GCLC, etc. | 2.03e-02 |  |
| HBP1 | CD8TEX | Breast | Precancer | SAMSN1,SARAF,GCLC, etc. | 0.00e+00 |  |
| HBP1 | CD4TN | Breast | Precancer | SAMSN1,SARAF,GCLC, etc. | 0.00e+00 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HBP1 | SNV | Missense_Mutation | novel | c.287N>T | p.Ser96Leu | p.S96L | O60381 | protein_coding | tolerated(0.2) | probably_damaging(0.95) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| HBP1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Pro340Thr | p.P340T | O60381 | protein_coding | deleterious(0.03) | possibly_damaging(0.669) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| HBP1 | SNV | Missense_Mutation | c.1423N>G | p.Met475Val | p.M475V | O60381 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HBP1 | SNV | Missense_Mutation | c.1388N>G | p.Ala463Gly | p.A463G | O60381 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HBP1 | insertion | Frame_Shift_Ins | novel | c.158_159insGCTAAGGGTTATTTTTGAGGGATATAGGCAGATAG | p.His53GlnfsTer37 | p.H53Qfs*37 | O60381 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| HBP1 | deletion | Frame_Shift_Del | c.1255delN | p.Asn420ThrfsTer7 | p.N420Tfs*7 | O60381 | protein_coding | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| HBP1 | deletion | Frame_Shift_Del | novel | c.870delN | p.Leu291TyrfsTer4 | p.L291Yfs*4 | O60381 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| HBP1 | SNV | Missense_Mutation | novel | c.948N>C | p.Leu316Phe | p.L316F | O60381 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HBP1 | SNV | Missense_Mutation | novel | c.1163G>A | p.Gly388Asp | p.G388D | O60381 | protein_coding | tolerated(0.05) | benign(0.01) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| HBP1 | SNV | Missense_Mutation | c.355A>G | p.Thr119Ala | p.T119A | O60381 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |